Compare YieldMax MSTR Option Income Strategy ETF (MSTY) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
YieldMax MSTR Option Income Strategy ETF vs Repligen Corporation Common Stock — how do they compare? YieldMax MSTR Option Income Strategy ETF trades at $14.24 (market cap $1.14B), while Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B). The key difference: Repligen Corporation Common Stock is far larger — about 9.8× YieldMax MSTR Option Income Strategy ETF's market cap, and Repligen Corporation Common Stock is trading nearer its 52-week high, YieldMax MSTR Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold YieldMax MSTR Option Income Strategy ETF for 31 Days and Repligen Corporation Common Stock for 0 Days on average.
| MSTY | RGEN | |
|---|---|---|
Market Cap | $1.14B | $11.14B |
Volume | 1,611,783 | 1,259,263 |
Sector | Income / Options Overlay | Health |
52-Week High | $63.60 | $194.57 |
52-Week Low | $11.55 | $102.87 |
Typical Hold Time | 31 Days | 0 Days |
Enterprise Value | — | $11.02B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MSTY trades at $15.52, down 0.13% on the day, with a bearish technical outlook as moving averages signal selling pressure. The ETF's high distribution rate, exceeding 100% annualized, is a key feature but has coincided with significant NAV erosion, as noted in recent financial media. Recent weekly dividend announcements from YieldMax highlight the income focus, but underlying asset volatility remains a concern.
The outlook is cautious; while the high yield is attractive for income-seeking investors, it comes with substantial risk of principal depletion. Analyst sentiment is mixed, balancing the tactical income opportunity against structural concerns about the fund's long-term sustainability in volatile markets.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About YieldMax MSTR Option Income Strategy ETF
MSTY is an actively managed ETF that pursues a synthetic covered call strategy on MicroStrategy Incorporated (MSTR) stock. The fund primarily sells call options on MSTR and invests in U.S. Treasury securities and other high-quality collateral. Its goal is to generate monthly income from the option premiums. This strategy provides exposure to the volatile, Bitcoin-correlated growth potential of MSTR while seeking to deliver a high yield, though it caps the potential capital appreciation of the stock.
Read more on MSTY →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
